We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Molecular Targeting Technologies Inc. (MTTI) and Evergreen Theragnostics Inc., have entered an agreement in which Evergreen will manufacture MTTI's EvaThera platform of radiopharmaceuticals.
Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, have entered into an agreement whereby Evergreen will provide U.S.-based ...
Precirix NV and Evergreen Theragnostics Inc. have entered into an agreement whereby Evergreen will provide US-based manufacturing for Precirix's lead product candidate, CAM-H2.